The Clinical Study Of The Recombinant Human Tumor Necrosis Factor-a Receptor â…¡:Igg Fc Fusion Protein For Injection And Tonifying The Kidney And Promoting The Circulation Of Blood In The Treatment Of Ankylosing Spondylitis

PurPoseTo evaluate the Efficaev of The Recombinant Human Tumor Necrosis Factor-a Receptor â…¡:IgG Fc Fusion Protein for Injection And Tonifying the Kidney and Promoting the circulation of blood in the treatment of Ankylosing Spondylitis.MethodThe qualified patients for this study were all diagnosed as ankylosing spondylitis with yang deficiency of the kidney, and were treated according to the principle of Tonifying the Kidney and promoting the circulation of blood. In all20qualified cases, the symptoms before and after treatment were observed. The curative effect of the method was assessed according to the Assessment of Ankylosing Spondylitis(ASAS)Results1. The efficaev of key indicators:After one, three and six months of the treatment, the major indices improved significantly(P<0.05).2. ASAS Assessment:After the first month of the treatment, only11scored ASAS20(55%), and only1scored ASAS50(5%) and none scored above ASAS70. At the end of the third month, there were8patients who seored ASAS20(40%),4patients scored ASAS50(20%) and2patients scored ASAS70(10%). Atthe end of the treatment, there were2Patients who scored ASAS20(10%),8patients scored ASAS50(40%) and5Patients scored ASAS70(25%).Conelusions Treating ankylosing spondylitis by The Recombinant Human Tumor Necrosis Factor-a Receptor â…¡:IgG Fc Fusion Protein for Injection And Tonifying the Kidney and Promoting the circulation of blood is proved to be effective in controlling and relieving clinical symptoms, which indicates that this kind of treatment can decrease the degree of inflammation thus allowing better joint mobility and function.